Article has no nextliveshere tags assigned

Article has no topics tags assigned

Article has no colleges tags assigned

Description is empty

Article has no audiences tags assigned

Article has no units tags assigned

Contacts are empty

These messages will display in edit mode only.

Phase I trials at UC examine safety of immunotherapies for cancer

Only offered locally at UC, the trials will study ways the immune system can be stimulated to fight lung and bladder cancers.

Two Phase I clinical trials are being offered at the University of Cincinnati (UC) to investigate the safety and use of novel immunotherapies for lung and bladder cancers.

John Morris and someone from his lab looking at a petri dish.

John Morris, MD (right), is the director of the Phase I Experimental Therapeutics Program, the only program of its kind locally. Photo credit: Colleen Kelley

Only offered locally at UC, these trials will study bioengineered antibodies being used to stimulate the immune system to attack cancerous cells for a more direct and effective approach to treating cancer.

“These trials are Phase I trials, meaning they are the first step in testing therapies in humans; they are trials intended to evaluate safe dosages, the best methods of administration of a therapy and frequency of administration,” says John Morris, MD, professor of medicine at the UC College of Medicine, UC Health oncologist and principal investigator on these trials. Morris also leads the UC Phase I Experimental Therapeutics Program, which is the only program of its kind locally. “Phase I trials typically include less than 30 people and are administered in a closely-monitored setting where patients can be observed and followed,” he adds.

Research like this is an example of the university’s innovation agenda, one of the key platforms of Next Lives Here, UC’s strategic direction. 

For the first trial, looking at therapies for lung cancer, researchers are studying a bioengineered antibody with two parts—one of which binds to programmed death-ligand 1 (PD-L1), an immune-suppressing protein produced by cancer cells which affects anti-cancer activity of T cells, and the other part binding to and blocking transforming growth factor-beta 1 (TGF-β1), a protein that stimulates cancer cell growth and decreases the body’s immune responses, in an effort to ramp up immunity and fight off cancerous cells.

For the second trial, researchers are studying the use of targeted Interleukin-12 (NHS-IL-12), a protein that stimulates the growth and function of T cells, and combining it with the drug avelumab, a Food and Drug Administration-approved anti-PD-L1 antibody treatment that has been used to treat other cancers, to target bladder cancer cells in patients that have not responded to standard therapy.

T cells are a type of white blood cell actively involved in the body’s immune response to seek out cancer cells and kill them.

Therapies will be administered intravenously or as a subcutaneous injection, and patients will be closely monitored for tumor response and side effects. 

“The hope with immunotherapies for cancer is to directly target the cancerous cells, leaving other healthy cells unharmed and eliminating side-effects for patients,” Morris says. “However, first, we must ensure that dosage and the way we administer the therapies to patients is safe and effective. We are hopeful that these types of therapies provide another option for patients undergoing care for lung and bladder cancers.”

Top photo credit: Colleen Kelley

For more information on how to enroll in these trials or others, call 513-584-0599.

Related Stories

UC researcher collaborates in gene-editing study in HIV patients

Wed, August 14, 2019

Carl Fichtenbaum, MD, professor in the Division of Infectious Diseases in the Department of Internal Medicine at the UC College of Medicine, is the local principal investigator on a study called TRAILBLAZER, which stands for T-Cell Reinfusion After Interfering With Lymphocyte Binding Location of AIDS Virus Through Zinc-finger-nuclease Elimination of CCR5 Receptors. The study will pinpoint and alter a specific gene in people with HIV. The hope is that process will lower the amount of HIV in the person’s body, and could possibly lead to the development of a cure for HIV.

White coats and words of wisdom for new UC medical students

Tue, August 13, 2019

CINCINNATI—Stay curious. Remain humble. Never forget that wearing the White Coat is a privilege. A wise sage offered this advice to new medical students during the 24th annual White Coat Ceremony held by the University of Cincinnati (UC) College of Medicine Aug. 9 at Aronoff Center in downtown Cincinnati. “I highly recommend pursuing what makes you curious,” said Tiffiny Diers, MD, associate professor in the Department of Internal Medicine. “Whether it is in what you are studying, in a patient story or career opportunities that come your way, curiosity and exploration yield discovery.” “The expansion of your own knowledge, what you can bring to your patients, and ultimately to our field, these are also antidotes to burnout in a challenging profession helping you to maintain a sense of meaning and engagement in your work,” said Diers. Diers, associate program director for the UC Internal Medicine Residency Program and a UC Health physician, offered the keynote address at the White Coat Ceremony. Her message was aimed at one of UC’s largest medical classes in recent years, and the most racially and ethnically diverse ever. The College of Medicine welcomed 185 newly admitted medical students during the ceremony. Each member of the class of 2023 was presented with a white coat symbolizing entry into the medical profession. UC College of Medicine alumni, faculty and staff provided the coats as a gift. The white coat is also a symbol of the patients the students will treat and the compassion, honesty and caring to which the students should always aspire. College of Medicine Interim Dean Andrew Filak Jr., MD, and UC President Neville Pinto also offered welcoming remarks to the class. “President Pinto has dubbed the university’s strategic direction ‘Next Lives Here’,” explained Filak. “Powered by knowledge, ideas and minds, Next Lives Here amplifies our core missions of teaching, research and service—from preparing faculty to teach tomorrow to pioneering the next cure to solving human-centered problems in the far corners of the globe. It is a culture that is owned, not rented and it is changing the way we live, work and learn. You are what is ‘Next’ for the College of Medicine. Our next class, our next generation of physicians, our next medical leaders who will impact the world.”

Debug Query for this